Regeneron, Sanofi Get CHMP Backing for Dupixent in Younger Children With CSU
Regeneron, Sanofi Get CHMP Backing for Dupixent in Younger Children With CSU is drawing significant interest across the industry.
By Colin Kellaher Regeneron Pharmaceuticals and Sanofi said a key European regulatory committee has recommended expanded approval of their blockbuster anti-inflammatory drug Dupixent for younger...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Nevada sues Kalshi for operating a sports gambling market without a license
- Swiss second home prices skyrocket
- Olympics-Crosscountry-Who let the dog out? Husky gatecrashes team sprint
- Concerns about the 'Inverted Food Pyramid' | Opinion
Source: Original →